Oncotype DX Recurrence Score and Germline BRCA Variants in Patients with HR-Positive/HER2-Negative Early Breast Cancer: A Retrospective Observational Study

Oncotype DX Recurrence Score and Germline BRCA Variants in Patients with HR-Positive/HER2-Negative Early Breast Cancer: A Retrospective Observational Study

Abstract Introduction The Oncotype DX (ODX) recurrence score (RS) is prognostic and predictive of chemotherapy benefit in patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. Data on the distribution of germline BRCA1 and/or BRCA2...

Full description

Saved in:
Bibliographic Details
Main Authors: Stefania Morganti, Rabia A. Khan, Luis C. Berrocal-Almanza, Miguel Miranda, Linlin Luo, Xiaoqing Xu, Ann H. Partridge, Filipa Lynce
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-04-01
Series:Oncology and Therapy
Subjects:
BRCA1/BRCA2 gene
BRCA testing
Early breast cancer
Genetic testing
Germline BRCA pathogenic variants
Germline BRCA variant HR-positive
Online Access:https://doi.org/10.1007/s40487-025-00332-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40487-025-00332-8

Similar Items